作者
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, Keunchil Park, Jürgen Wolf, Yasir Elamin, Hannah M Davis, Victoria Soldatenkova, Andreas Sashegyi, Aimee Bence Lin, Boris K Lin, Herbert H F Loong, Silvia Novello, Edurne Arriola, Maurice Pérol, Koichi Goto, Fernando C Santini
发表日期
2021/3
来源
Future Oncology
卷号
17
期号
7
页码范围
763-773
出版商
Future Medicine Ltd
简介
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.
Clinical trial registration: NCT04194944 (ClinicalTrials.gov)
学术搜索中的文章
BJ Solomon, CC Zhou, A Drilon, K Park, J Wolf… - Future Oncology, 2021